Global Mesalazine Market Outlook 2022

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
The industry's leading manufacturers are Syntese A/S, Divis Laboratories and Cambrex Corporation, which accounted for 24.07%, 12.91% and 6.61% of revenues in 2019, respectively. In terms of regions, the revenue share in Europe is the highest, reaching 46.73% in 2019.

The global Mesalazine market was valued at US$ 142.4 million in 2020 and is expected to reach US$ 189 million by the end of 2027, growing at a CAGR of 4.1% during 2021-2027.
This report focuses on Mesalazine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Mesalazine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Mesalazine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Purity ≥ 97 %
Purity ≥ 98 %
Purity ≥ 99 %

Segment by Application
Tablets
Capsules
Pellet and Granule
Suppository
Enema
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
PharmaZell
Syntese A/S
Cambrex Corporation
Divis Laboratories
Chemi SpA
Ipca Laboratories
Hangzhou Brother
Lianyungang Fengheng Biopharm
Lasa Loboratory
Corden Pharma Bergamo
Erregierre SpA
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical